NHS to reimburse Hemlibra
The ‘life-changing’ drug will be reimbursed for certain people with severe congenital haemophilia A.
Read More
Tag: emicizumab
Roche presents positive late-stage Hemlibra data
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly.
Read More
Roche’s Hemlibra shows sustained bleed control in children
Roche’s Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Read More
NHS England clears specialised treatments for NHS use
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Read More
Roche/Chugai’s Hemlibra wins green light for bleeding disorder
The European Commission has licensed Roche/Chugai’s Hemlibra for the routine prevention of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Read More
Seven medicines leap closer to EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Read More
Roche’s emicizumab cleared for early access in the UK
Roche’s emicizumab in being included in the UK’s Early Access to Medicines Scheme for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Read More
Roche’s Hemlibra reduces bleeds in haemophilia A patients
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
Read More
Roche bags new approvals for Hemlibra, Gazyva
US regulators have issued a green light for Roche’s haemophilia A therapy Hemlibra and also expanded the scope of Gazyva to include untreated advanced follicular lymphoma.
Read More
Roche’s haemophilia drug cut bleeds by 87 percent in trial
Roche has presented a new batch of data showing that its experimental bispecific monoclonal antibody emicizumab significantly reduced bleeds in patients with haemophilia A and inhibitors to factor VIII.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
